Article
Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations.
Critical reviews in oncology/hematology - 1 May 2015
Haspinger Eva Regina, Agustoni Francesco, Torri Valter, Gelsomino Francesco, Platania Marco, Zilembo Nicoletta, Gallucci Rosaria, Garassino Marina Chiara, Cinquini Michela
Abstract excerpt
Three EGFR tyrosine kinase inhibitors have been compared to standard chemotherapy as up-front treatment in patients with advanced EGFR-positive NSCLC. We performed a systematic review and meta-analysis using indirect comparisons to estimate the risk/benefit associated with each drug. EGFR-TKIs fa...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.